Effect of Reboxetine on Major Depressive Disorder in Breast Cancer Patients

2004 ◽  
Vol 65 (4) ◽  
pp. 515-520 ◽  
Author(s):  
Luigi Grassi ◽  
Bruno Biancosino ◽  
Luciana Marmai ◽  
Roberto Righi
Keyword(s):  
Breast Cancer ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Major Depressive

Risk of Developing Depression among Breast Cancer Patients in Palestine

2021 ◽  
Author(s):  
Dana Sadaqa ◽  
Ahlam Farraj ◽  
Hani Naseef ◽  
Hamza Alsaid ◽  
Nimeh Alshami ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Treatment Outcomes ◽  
Cancer Patients ◽  
Severe Depression ◽  
Breast Cancer Patients ◽  
Major Depressive

Abstract Background: Breast cancer (BC) is the most common cancer among women. Studies have shown that cancer patients can develop depression impacting their quality of life, treatment outcomes, and survival rates. This study aimed to determine the risk factors, severity and prevalence of depression among females diagnosed with BC in multiple hospitals across Palestine.Methods: a cross-sectional study was conducted at different cancer treatment centers in Palestine using a previously developed questionnaire consisting of 23 questions to assess the severity of major depressive disorder among females diagnosed with breast cancer. The Patient Health Questionnaire-9 (PHQ-9) was included in the questionnaire. Results: Out of 223 respondents, 79 (35.4%) have developed moderate to severe depression. Chi-square results revealed that the risk of developing moderate to severe depression was higher among females who suffer from side-effects related to BC treatment (P<0.011), females who knew the BC stage at the diagnosis step (P<0.031), and negative implications on BC patients in Palestine (P<0.009).Conclusion: Breast cancer patients have an increased risk of developing major depressive disorder. Patient assessment and treatment for depression at the time of BC diagnosis, during the treatment journey, and monitoring after treatment completion is essential for patient quality of life and BC treatment outcomes.

Interleukin-6 levels and HPA axis activation in breast cancer patients with major depressive disorder

2007 ◽  
Vol 31 (6) ◽  
pp. 1242-1247 ◽  
Author(s):  
Haldun Soygur ◽  
Ozden Palaoglu ◽  
Eyüp Sabri Akarsu ◽  
Eylem Sahin Cankurtaran ◽  
Elvan Ozalp ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Cancer Patients ◽  
Hpa Axis ◽  
Interleukin 6 ◽  
Breast Cancer Patients ◽  
Major Depressive

Validation of the Brief Edinburgh Depression Scale (BEDS) in a Mexican population with advanced cancer in a palliative care service

2018 ◽  
Vol 17 (04) ◽  
pp. 436-440 ◽  
Author(s):  
Oscar Rodríguez-Mayoral ◽  
Bárbara Rodríguez-Ortíz ◽  
Leticia Ascencio-Huertas ◽  
Adriana Peña-Nieves ◽  
Emma Verástegui ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Depression Scale ◽  
Case Finding ◽  
Spanish Language ◽  
Advanced Cancer Patients ◽  
Major Depressive ◽  
Palliative Patients

AbstractObjectiveDepression in palliative advanced cancer patients is common, but often goes unrecognized. One of the first steps toward improving detection is the development of tools that are valid in the specific language and setting in which they are to be used. The Brief Edinburgh Depression Scale (BEDS) is a sensitive case-finding tool for depression in advanced cancer patients that was developed in the United Kingdom. There are no validated instruments to identify depression in Mexican palliative patients. Our aim was to validate the Spanish-language version of the BEDS in Mexican population with advanced cancer.MethodWe conducted a cross-sectional study with outpatients from the palliative care unit at the Instituto Nacional de Cancerología in Mexico City. The Mexican BEDS was validated against a semistructured psychiatric clinical interview according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, classification criteria for major depressive disorder. The interviewer was blind to the BEDS score at the time of the assessment.ResultSeventy subjects completed the scale and interview. Women represented 71.4% of the sample and median age of subjects was 56.5 years (range, 20–85 years). The prevalence of major depressive disorder according to the psychiatric interview was 20%. The most valid cutoff for defining a case of depression was a score ≥5 of 18 on the Mexican BEDS, which gave a sensitivity of 85.7% and specificity of 62.5%. The scale's Cronbach's alpha was 0.71.Significance of resultsMajor depressive disorder is frequent in Mexican palliative patients. The Spanish-language Mexican version of the BEDS is the first valid case-finding tool in advanced cancer patients in this setting.

Rates and risks of suicidality in young adults (YAs) with advanced cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 9015-9015
Author(s):  
Kelly Marie Trevino ◽  
Karen Fasciano ◽  
Holly Gwen Prigerson
Keyword(s):  
Quality Of Life ◽  
Social Support ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Cancer Patients ◽  
Advanced Cancer ◽  
Performance Status ◽  
Major Depressive ◽  
Targeted Interventions

9015 Background: Suicide rates in YA cancer patients are higher than in the general population. Although cancer is associated with a four-fold increase in the likelihood of a suicide attempt, little is known about suicidality in YAs with cancer. This study examined rates and clinical risk factors associated with suicidality in a sample of YAs with advanced cancer. Methods: Structured interviews were conducted between 4/2010 and 9/2011 with 70 YA advanced cancer patients (range 20-40 yrs, M=33.97, SD=5.61) receiving care at the Dana-Farber Cancer Institute. Validated measures assessed suicidality (i.e., Yale Evaluation of Suicidality), quality of life, major depressive disorder, grief over cancer-related losses, and social support. Scores on the suicidality measure were dichotomized into positive screen = 1 and negative screen = 0. Chi-square, t-test, and logistic regression analyses evaluated the relationship between suicidality and participant characteristics and psychosocial variables, controlling for confounding variables. Results: Over one-fifth (21.4%) of the sample screened positive for suicidality. Female gender χ2(1, N = 70) = 4.95, p = .026), breast compared with other cancer diagnosis χ2(1, N = 70) = 5.66, p = .017), and better performance status (t(68) = 3.13, p < .01) were associated with lower rates of suicidality. Participants who met criteria for current (OR [95% CI] 8.67 [1.78, 42.22]) or lifetime major depressive disorder (5.38 [1.60, 18.12]) endorsed higher rates of suicidality. Better overall (.97 [.94, .99]), psychological (.93 [.87, .94]), and existential quality of life (.91 [.85, .98]) were associated with reduced suicidality risk. More severe grief was associated with greater risk (1.15 [1.04, 1.28]) whereas greater social support was associated with lower suicidality risk (.85 [.74, .97]). Conclusions: YAs with advanced cancer reported higher rates of suicidality than observed in other age groups. Developmentally targeted interventions that promote physical function, effectively treat depression, improve quality of life and reduce grief, and provide opportunities for social support may reduce rates of and risk for suicidality in this population.

Potential prognostic value of clinical characteristics, hormone status and major depressive disorder in breast cancer

2017 ◽  
Vol 13 (17) ◽  
pp. 1493-1503 ◽  
Author(s):  
Lingyun Hui ◽  
Tianhe Huang ◽  
Jie Lian ◽  
Fuling Zhou ◽  
Chengge Gao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Prognostic Value ◽  
Clinical Characteristics ◽  
Major Depressive ◽  
Hormone Status

scholarly journals Screening for Depression in Younger Breast Cancer Survivors: Outcomes from Use of the Patient Health Questionnaire-9 (PHQ-9)

2021 ◽  
Author(s):  
Patricia A Ganz ◽  
Julienne E Bower ◽  
Ann H Partridge ◽  
Antonio C Wolff ◽  
Elissa D Thorner ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Major Depressive Disorder ◽  
Depressive Symptoms ◽  
Depressive Disorder ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Depression Screening ◽  
Health Questionnaire ◽  
Major Depressive ◽  
Patient Health

Abstract Background Major cancer organizations recommend depression screening in patients and survivors. The Patient Health Questionnaire-9 (PHQ-9) is often suggested, with limited information about its use. Methods Enrollment data collected from younger breast cancer survivors participating in a behavioral intervention trial were used to examine the relationship between PHQ-9 scores (range = 0-27), patient characteristics and responses to standardized psychosocial assessment tools. Major depressive disorder criterion was met if responses to the first two PHQ-9 items (range = 0-6) were &gt;3. The sample was categorized by total PHQ-9 scores: &lt;5 (minimal depressive symptoms), 5-9 (mild to moderate depressive symptoms) and &gt;10 (moderate to severe depression). PHQ-9 category associations with medical, demographic, psychosocial and behavioral characteristics were examined using ANOVA for continuous variables and chi-square tests for categorical variables. Results 231 women met the study pre-screening eligibility criterion of mild depressive symptoms and enrolled in the study. On average, they were 45.2 years old and 2.6 years since diagnosis. At enrollment, 22.1% met the screening criterion for possible major depressive disorder; among those with PHQ-9 scores &gt;10, 58.3% met this criterion. Anxiety, fatigue, insomnia, and intrusive thoughts about cancer were frequent and were associated with depressive symptom severity (all Ps &lt;.001). In contrast, neither demographic nor cancer treatment characteristics were associated with depressive symptoms. Conclusions Depressive symptoms in this selected sample of younger breast cancer survivors were independent of demographic characteristics or cancer treatment history, suggesting that depression screening is necessary to detect uncontrolled depressive symptoms.

Sign in / Sign up

Export Citation Format

Share Document